

Government Gazette

of the State of

New South Wales

Number 496–Health and Education
Friday, 1 October 2021

The New South Wales Government Gazette is the permanent public record of official NSW Government notices. It also contains local council, non-government and other notices.

Each notice in the Government Gazette has a unique reference number that appears in parentheses at the end of the notice and can be used as a reference for that notice (for example, (n2019-14)).

The Gazette is compiled by the Parliamentary Counsel's Office and published on the NSW legislation website (www.legislation.nsw.gov.au) under the authority of the NSW Government. The website contains a permanent archive of past Gazettes.

To submit a notice for gazettal, see the Gazette page.

ISSN 2201-7534

By Authority
Government Printer

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Withdrawal of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation 2008* an Order has been made on **Mr Angus Gregory Naylor (PHA0002480012)**, of SUTHERLAND NSW 2232, prohibiting him, until further notice, as a pharmacist, from supplying or having possession of, or manufacturing any preparation, admixture or extract of a drug of addiction as authorised by clauses 101(1) and 102 of the Regulation.

This Order is to take effect on and from 1 October 2021.

Dated at Sydney, 29 September 2021.

ELIZABETH KOFF
Secretary, NSW Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

ORDER

Restoration of Drug Authority

In accordance with the provisions of clause 175(1) of the *Poisons and Therapeutic Goods Regulation 2008* a direction has been issued that the Order that took effect on and from 9 December 2011, on **Dr Asaad Baraz (MED0001188199)** of Lithgow NSW 2790, prohibiting him as a medical practitioner, from supplying, having possession of or issuing a prescription for a drug of addiction as authorised by clauses 101 and 77 of the Regulation, shall cease to operate on and from 1 October 2021.

Dated at Sydney, 29 September 2021.

ELIZABETH KOFF
Secretary, NSW Health

Approval
Poisons and Therapeutic Goods Regulation 2008 (NSW)

I, Kerry Chant, Chief Health Officer and delegate of the Secretary NSW Health, under clause 48A(1A)(d) of the *Poisons and Therapeutic Goods Regulation 2008* (NSW) and section 43 of the *Interpretation Act 1987* do hereby:

1. revoke the approval instrument signed on 8 September 2021 and published in NSW Government Gazette 443 on 10 September 2021.
2. approve the ***Vaxzevria ChAdOx1-S COVID-19 vaccine*** ('AstraZeneca vaccine'), ***Comirnaty (BNT162b2 [mRNA]) COVID-19 vaccine*** ('Pfizer vaccine') and the ***Spikevax (elasomeran) COVID-19 vaccine*** ('Moderna vaccine'), collectively '***an approved vaccine***', for the purposes of that clause. Pursuant to clause 48A(1B), this approval is subject to the following conditions:
   a. The pharmacist must not supply or administer:
      i. the AstraZeneca vaccine to a person who is under the age of 18 years old.
      ii. the Pfizer vaccine to a person who is under the age of 12 years old.
      iii. the Moderna vaccine to a person who is under the age of 12 years old.
   b. The pharmacist must obtain written or other electronic evidence of consent from each patient (or parent, guardian or substitute decision-maker in the case of a person who cannot consent for themselves) to whom an approved vaccine is supplied and retain a copy of that consent. The Australian Government Department of Health *COVID-19 vaccination – Consent form for COVID-19 vaccination* is to be used in obtaining consent.
   c. The pharmacist must not supply or administer an approved vaccine to a person who has experienced a serious adverse event after the first administration of an approved vaccine.
   d. The pharmacist must not supply or administer an approved vaccine to a person with a contra-indication or precaution to vaccination listed in the 'The digital Australian Immunisation Handbook', or in the Australian Technical Advisory Group on Immunisation (ATAGI) advice or guidance, or in the approved product information for the product unless the only contraindication or precaution:
      i. *For any approved vaccine*: is that a person is on anti-coagulant therapy; or
      ii. *For Pfizer vaccine or Moderna vaccine*: is that a person is pregnant.
   e. The pharmacist must provide each patient (or parent, guardian or substitute decision-maker) with the Australian Government advice in relation to what to expect following vaccination with an approved vaccine, and when to seek medical attention following each administration of the vaccine.
   f. The pharmacist must ensure they remain up to date on any new advice from the Australian Technical Advisory Group on Immunisation (ATAGI) or Therapeutic Goods Administration (TGA) regarding additional precautions or consent requirements for an approved vaccine.

In this instrument:

- '***pharmacist***' means a registered pharmacist or a pharmacist who is provisionally registered and undertaking approved supervised practice who administers the approved vaccine:
  - in a pharmacy business approved under Schedule 5F of the *Health Practitioner Regulation National Law* that has registered to participate in the COVID-19 vaccination program
  - in a residential care facility (as defined under the *Poisons and Therapeutic Goods Regulation 2008*)
  - in a general practice clinic registered to participate in the COVID-19 vaccination program
  - in an Aboriginal Medical Service that has registered to participate in the COVID-19 vaccination program
  - as part of a staff occupational health clinic (clinics in the workplace to vaccinate employees); or
  - as part of a vaccination service provided by the Royal Flying Doctor Service of Australia.

This approval can be revoked at any time.

Kerry Chant
Chief Health Officer
Dated 28 September 2021